Bristol-Myers Squibb Analyst Ratings
BenzingaApr 18 23:03
Wells Fargo Maintains Equal-Weight on Bristol-Myers Squibb, Raises Price Target to $52
BenzingaApr 18 23:04
Analysts' Opinions Are Mixed on These Healthcare Stocks: Accolade (ACCD), Ultragenyx Pharmaceutical (RARE) and Bristol-Myers Squibb (BMY)
TipRanksApr 18 18:10
Jefferies Cuts Bristol-Myers Squibb's Price Target to $56 From $58
MT NewswiresApr 12 19:37
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bristol-Myers Squibb (BMY) and Roche Holding AG (OtherRHHVF)
TipRanksApr 12 18:00
Bristol-Myers Squibb: A Buy Rating on Undervaluation and Promising Product Portfolio
TipRanksApr 12 17:25
Hold Rating on Bristol-Myers Squibb Amid Promising Yet Incomplete KarXT Schizophrenia Trial Data
TipRanksApr 10 14:18
Morgan Stanley Trims Price Target on Bristol-Myers Squibb to $40 From $41, Keeps Underweight Rating
MT NewswiresApr 9 20:05
Bristol-Myers Squibb's Hold Rating: Balancing KarXT's Efficacy and Safety With Financial Uncertainties
TipRanksApr 8 17:47
Wells Fargo Sticks to Its Hold Rating for Bristol-Myers Squibb (BMY)
TipRanksApr 3 17:16
BTIG Upgrades Nuvation to Buy, Cites AnHeart Acquisition
Seeking AlphaMar 27 01:37
Hold Rating on Bristol-Myers Squibb Amidst NSCLC Trial Uncertainties and Pending KarXT Results
TipRanksMar 19 13:37
Hold Rating on Bristol-Myers Squibb Amid Mixed Clinical Outcomes and Market Competition
TipRanksMar 18 17:15
Hold Rating on Bristol-Myers Squibb Amid Concerns Over Abecma's Efficacy and Safety
TipRanksMar 14 19:16
Truist Financial Keeps Their Buy Rating on Bristol-Myers Squibb (BMY)
TipRanksMar 12 20:37
Societe Generale Downgrades Bristol-Myers Squibb to Hold From Buy, Cuts Price Target to $51 From $85
MT NewswiresMar 12 01:49
UBS Cuts BioXcel to Neutral; Cites Regulatory Issues, Financing
Seeking AlphaFeb 22 00:03
Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR), Waters (WAT) and Bristol-Myers Squibb (BMY)
TipRanksFeb 7 21:30
Bristol-Myers Squibb Analyst Ratings
BenzingaFeb 6 19:25
Redburn Cuts Bristol-Myers Squibb Price Target to $54
InvestingFeb 6 18:12
No Data
No Data